The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“Remarkably, an initial report published in 1999 indicated that thalidomide was an effective treatment in 30–40% of patients with advanced and refractory M”
BackgroundThalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Haslett, P. A. J., Corral, L. G., Albert, M., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 573
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Cited by
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Ribosomopathies: human disorders of ribosome dysfunction
Narla, A., & Ebert, B. L. (2010) · Blood · doi:10.1182/blood-2009-10-178129 · Cited by 809
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Cancer and the tumor microenvironment: a review of an essential relationship
Mbeunkui, F., & Johann, D. J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0881-9 · Cited by 487
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., & Bartlett, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4405 · Cited by 440
Self-citationTargeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Galustian, C., Meyer, B., Labarthe, M.-C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0620-4 · Cited by 391
Self-citationPrimary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.049 · Cited by 381
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G., Vose, J. M., Cole, C. E., Lam, W., McBride, K., Wride, K., Pietronigro, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3429 · Cited by 371
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Dong, G., Ding, Y., He, S., & Sheng, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00895 · Cited by 369
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.08.033 · Cited by 347
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Immunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O., & Moss, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 341
Nimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 336
Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 319
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
Dispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K., Geyer, S. M., Lust, J. A., Allred, J. B., Witzig, T. E., Rajkumar, S. V., et al. (2007) · Blood · doi:10.1182/blood-2006-07-032987 · Cited by 273
Chang, D. H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S. D., Jagannath, S., & Dhodapkar, M. V. (2006) · Blood · doi:10.1182/blood-2005-10-4184 · Cited by 271
Dredge, K., Horsfall, R., Robinson, S. P., Zhang, L.-H., Lu, L., Tang, Y., Shirley, M. A., Muller, G., Schafer, P., Stirling, D., et al. (2005) · Microvascular Research · doi:10.1016/j.mvr.2005.01.002 · Cited by 268
Self-citationMajor advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Alabi, S. B., & Crews, C. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100647 · Cited by 261
Witzig, T. E., Wiernik, P. H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1169 · Cited by 260
Melchert, M., & List, A. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.022 · Cited by 246
Hughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505237 · Cited by 236
Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood · doi:10.1182/blood.2020008676 · Cited by 229
Targeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4128 · Cited by 183
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176
Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141614 · Cited by 176
Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162
Ishida, T., Fujiwara, H., Nosaka, K., Taira, N., Abe, Y., Imaizumi, Y., Moriuchi, Y., Jo, T., Ishizawa, K., Tobinai, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.7732 · Cited by 152
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
p63 is a cereblon substrate involved in thalidomide teratogenicity
Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0366-7 · Cited by 134
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer, N. J., Liu, X., Magin, R. S., Doherty, L. M., Chan, W. C., Ficarro, S. B., Hu, W., Roberts, R. M., Iacob, R. E., Stolte, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62076-x · Cited by 125
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M. (2014) · Blood · doi:10.1182/blood-2013-09-525915 · Cited by 93
“Lenalidomide (Revlimid), an oral immunomodulatory drug and analog of thalidomide, is currently approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome, refractory/relapsedmultiplemyeloma, andmantle cell lymphoma.(18-20) The immunomodulatory properties such as natural killer (NK)-…”
BackgroundStructural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
Furihata, H., Yamanaka, S., Honda, T., Miyauchi, Y., Asano, A., Shibata, N., Tanokura, M., Sawasaki, T., & Miyakawa, T. (2020) · Nature Communications · doi:10.1038/s41467-020-18488-4 · Cited by 89
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
Thalidomide mimics uridine binding to an aromatic cage in cereblon
Hartmann, M. D., Boichenko, I., Coles, M., Zanini, F., Lupas, A. N., & Hernandez Alvarez, B. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.10.010 · Cited by 83
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40385-9 · Cited by 73
A novel cereblon modulator for targeted protein degradation
Kim, S. A., Go, A., Jo, S.-H., Park, S. J., Jeon, Y. U., Kim, J. E., Lee, H. K., Park, C. H., Lee, C.-O., Park, S. G., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.023 · Cited by 72
Phase I study of oral lenalidomide in patients with refractory metastatic cancer
Dahut, W. L., Aragon‐Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., & Figg, W. D. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009335001 · Cited by 56
Metadata
- Authors
- Bartlett, J. B., Dredge, K., & Dalgleish, A. G.
- Venue
- Nature Reviews Cancer
- Published
- 2004-04
- Volume
- 4
- Issue
- 4
- Pages
- 314-322
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1597238753
- Cited by
- 809
- References
- 53
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.